Bruton's Tyrosine Kinase Hematological Cancer Market

Key Highlights

• According to Cerhan and Habermann (2021), incidence rate for Marginal Zone Lymphoma (MZL) was 19.6 per 1,000,000 person-years; 9% of MZL cases were splenic MZL (SMZL), 30% nodal MZL (NMZL), and 61% extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT).

• As Per NORD, mantle cell lymphoma (MCL) is an uncommon form of non-Hodgkin’s lymphoma (NHL), accounting for 5–7% of all cases of NHL; about 1 out of 200,000 people worldwide is diagnosed each year with MCL. The disease primarily affects older adults, with males representing approximately three-quarters of those with MCL. Many affected individuals are diagnosed at about 60–70 years old. Reports suggest that most individuals with MCL have advanced (i.e., stage III or stage IV) disease at diagnosis.

• Bruton’s Tyrosine Kinase Hematological Cancer epidemiology is segmented as Total Cases of Hematological Cancer, Treatable cases by line of therapies, and Patients on Bruton's Tyrosine Kinase Hematological Cancer] in the Bruton's Tyrosine Kinase Hematological Cancer market report.

Request for unlock CAGR of Bruton's Tyrosine Kinase Hematological Cancer Market

DelveInsight's "Bruton’s tyrosine kinase Hematological Cancer Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Bruton’s Tyrosine Kinase Hematological Cancer, historical and forecasted epidemiology as well as the Bruton’s Tyrosine Kinase Hematological Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Bruton’s Tyrosine Kinase Hematological Cancer market report provides current treatment practices, emerging drugs, Bruton’s Tyrosine Kinase Hematological Cancer market share of the individual therapies, current and forecasted Bruton’s Tyrosine Kinase Hematological Cancer market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Bruton’s Tyrosine Kinase Hematological Cancer treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• Study Period: 2019–2032

Bruton’s Tyrosine Kinase Hematological Cancer Market: Understanding and Treatment Algorithm

The DelveInsight’s Bruton’s Tyrosine Kinase Hematological Cancer market report gives a thorough understanding of Bruton’s Tyrosine Kinase Hematological Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Bruton tyrosine kinase (BTK) inhibitors are now well established to treat several hematological malignancies. BTK is a non-receptor tyrosine kinase, which plays a central role in B-cell signaling and is necessary for normal B-cell development in the bone marrow involved in adaptive and innate receptor-mediated signals. Chronic activation of the B-cell Receptor pathway is a key driver of B-cell non-Hodgkin lymphomas, and hence, downstream blockade of this pathway utilizing BTK inhibitors (BTKi) in these diseases has proven very effective to date.

Hematological malignancies (blood cancers) are the fifth most common cancer group in economically developed regions globally. This cancer most often begins in the bone marrow, where blood is produced. Stem cells in the bone marrow develop into white blood cells, red blood cells, or platelets. Blood cancers occur when the uncontrolled growth of abnormal blood cells overtakes the development of normal blood cells and interferes with the regular functions of these cells. They are traditionally categorized by site according to whether cancer is first detected in the blood (leukemias), lymph nodes (lymphomas – Hodgkin and non-Hodgkin), or bone (myelomas). Although the latest and most suitable chemotherapy drugs for targeted tumors are important to improve the Bruton’s Tyrosine Kinase Hematological Cancer clinical trial outcomes of patients with hematologic malignancies.

Bruton tyrosine kinase (BTK) was initially implicated in the pathogenesis of X-linked agammaglobulinemia. The gene encoding the BTK molecule was isolated in 1993 and was named independently at the time as B cell progenitor kinase and agammaglobulinemia tyrosine kinase

Bruton’s tyrosine kinase Hematological Cancer Diagnosis

Current methods and techniques in diagnosing hematologic malignancies include biopsy, peripheral blood testing, bone marrow biopsy, immunology testing, flow cytometry, radiologic examination, chromosome analysis, DNA sequencing technology, etc.

Bruton’s tyrosine kinase Hematological Cancer Treatment

Inhibition of BTK has revolutionized the treatment landscape for patients with hematological malignancies. Till now, three BTK inhibitors – Imbruvica (ibrutinib), Calquence (acalabrutinib), and Brukinsa (zanubrutinib) – are approved by the US FDA, and many upcoming BTKs are present in the pipeline as well.

Bruton’s tyrosine kinase Hematological Cancer Epidemiology

The Bruton’s Tyrosine Kinase Hematological Cancer epidemiology section provides insights about historical and current Bruton’s Tyrosine Kinase Hematological Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• According to Cerhan and Habermann (2021), incidence rate for Marginal Zone Lymphoma (MZL) was 19.6 per 1,000,000 person-years; 9% of MZL cases were splenic MZL (SMZL), 30% nodal MZL (NMZL), and 61% extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT).

• As Per NORD, mantle cell lymphoma (MCL) is an uncommon form of non-Hodgkin’s lymphoma (NHL), accounting for 5–7% of all cases of NHL; about 1 out of 200,000 people worldwide is diagnosed each year with MCL. The disease primarily affects older adults, with males representing approximately three-quarters of those with MCL. Many affected individuals are diagnosed at about 60–70 years old. Reports suggest that most individuals with MCL have advanced (i.e., stage III or stage IV) disease at diagnosis.

• The disease epidemiology covered in the report provides historical as well as forecasted Bruton’s Tyrosine Kinase Hematological Cancer epidemiology [segmented as Total Cases of Hematological Cancer, Treatable cases by line of therapies, and Patients on BTK inhibitors] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Bruton’s tyrosine kinase Hematological Cancer Epidemiology

This section provides glimpse of the Bruton’s Tyrosine Kinase Hematological Cancer epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Bruton’s tyrosine kinase Hematological Cancer Drug Chapters

The drug chapter segment of the Bruton’s Tyrosine Kinase Hematological Cancer report encloses the detailed analysis of Bruton’s Tyrosine Kinase Hematological Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Bruton’s Tyrosine Kinase Hematological Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Bruton’s tyrosine kinase Hematological Cancer Marketed Drugs

IMBRUVICA (ibrutinib): Janssen

It was the first-generation BTK inhibitor that came to market in 2013, when it was approved by the FDA to treat adult patients with mantle cell lymphoma. It was approved by the FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL; relapsed after 1 prior therapy). The European Medicines Agency (EMA) approved this drug for adult patients with relapsed/refractory (R/R) MCL and patients with CLL.

CALQUENCE (acalabrutinib): AstraZeneca

It is a second-generation BTK inhibitor, is approved by the FDA to treat adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL; relapsed after 1 prior therapy); and by the EMA to treat adult patients with CLL or R/R MCL.

BRUKINSA (zanubrutinib): BeiGene

It is a selective next-generation covalent BTK inhibitor, is approved by the FDA to treat adult patients with mantle cell lymphoma (MCL) who have received prior therapy.

Note: Detailed Current therapies assessment will be provided in the full report of Bruton’s Tyrosine Kinase Hematological Cancer

Bruton’s tyrosine kinase Hematological Cancer Emerging Drugs

Pirtobrutinib is an investigational, oral, highly-selective non-covalent BTK inhibitor, being developed by Loxooncology. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required to develop, activate, and survive normal white blood cells, known as B-cells and malignant B-cells.

NX-5948 is an oral small molecule degrader of BTK, being developed by Nurix Therapeutics. Its activity is supported by preclinical data, in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance.

Note: Detailed emerging therapies assessment will be provided in the full report of Bruton’s Tyrosine Kinase Hematological Cancer

Bruton’s tyrosine kinase Hematological Cancer Market Outlook

Hematological cancer is an area that experts are still studying, and many potential drug candidates are being analyzed for their therapeutic effects. In the coming years, with the emergence of new drugs, the market for the treatment of hematological cancer is expected to witness positive changes. BTK inhibitors are increasingly used in MCL as chronic suppressive therapy, especially in the elderly.  BTK inhibitors were the most preferred agents in second or later lines of therapy (57%).

The dynamics of Bruton’s Tyrosine Kinase Hematological Cancer market is anticipated to change in the coming years owing to improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the launch of emerging therapies. Key players such as Loxooncology, BeiGene, Nurix Therapeutic and others are involved in developing therapies for Bruton’s Tyrosine Kinase Hematological Cancer.

According to DelveInsight, Bruton’s Tyrosine Kinase Hematological Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of Bruton’s Tyrosine Kinase Hematological Cancer is very robust, many potential therapies are being investigated for the treatment of Bruton’s Tyrosine Kinase Hematological Cancer, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Bruton’s Tyrosine Kinase Hematological Cancer market in the 7MM. Aside from that, the market size of Bruton’s Tyrosine Kinase Hematological Cancer may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

• The market growth of Bruton’s Tyrosine Kinase Hematological Cancer may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Bruton’s tyrosine kinase Hematological Cancer Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Bruton’s Tyrosine Kinase Hematological Cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers Bruton’s Tyrosine Kinase Hematological Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of Bruton’s Tyrosine Kinase Hematological Cancer.

Bruton’s tyrosine kinase Hematological Cancer Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Bruton’s Tyrosine Kinase Hematological Cancer key players involved in developing targeted therapeutics.

Bruton’s tyrosine kinase Hematological Cancer Clinical Trial Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Bruton’s Tyrosine Kinase Hematological Cancer emerging therapies.

Reimbursement Scenario in Bruton’s tyrosine kinase Hematological Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Bruton’s Tyrosine Kinase Hematological Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Bruton’s Tyrosine Kinase Hematological Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Bruton’s Tyrosine Kinase Hematological Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Bruton’s tyrosine kinase Hematological Cancer Market Report

• The report covers the descriptive overview of Bruton’s Tyrosine Kinase Hematological Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Bruton’s Tyrosine Kinase Hematological Cancer epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Bruton’s Tyrosine Kinase Hematological Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Bruton’s Tyrosine Kinase Hematological Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global Bruton’s Tyrosine Kinase Hematological Cancer Market

Bruton’s Tyrosine Kinase Hematological Cancer Market Report Highlights

• In the coming years, the Bruton’s Tyrosine Kinase Hematological Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Bruton’s Tyrosine Kinase Hematological Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for Bruton’s Tyrosine Kinase Hematological Cancer. The launch of emerging therapies will significantly impact the Bruton’s Tyrosine Kinase Hematological Cancer market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bruton’s Tyrosine Kinase Hematological Cancer
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Bruton’s Tyrosine Kinase Hematological Cancer clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Bruton’s tyrosine kinase Hematological Cancer Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Bruton’s Tyrosine Kinase Hematological Cancer Pipeline Analysis
• Bruton’s Tyrosine Kinase Hematological Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Bruton’s tyrosine kinase Hematological Cancer Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Bruton’s Tyrosine Kinase Hematological Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Bruton’s tyrosine kinase Hematological Cancer Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Bruton’s Tyrosine Kinase Hematological Cancer drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Bruton’s Tyrosine Kinase Hematological Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Bruton’s Tyrosine Kinase Hematological Cancer market size during the forecast period (2019-2032)?
• At what CAGR, the Bruton’s Tyrosine Kinase Hematological Cancer market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Bruton’s Tyrosine Kinase Hematological Cancer market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Bruton’s Tyrosine Kinase Hematological Cancer market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Bruton’s Tyrosine Kinase Hematological Cancer?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Bruton’s Tyrosine Kinase Hematological Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Bruton’s Tyrosine Kinase Hematological Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Bruton’s Tyrosine Kinase Hematological Cancer?
• Out of all 7MM countries, which country would have the highest patient population of Bruton’s Tyrosine Kinase Hematological Cancer during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Bruton’s Tyrosine Kinase Hematological Cancer treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Bruton’s Tyrosine Kinase Hematological Cancer in the USA, Europe, and Japan?
• What are the Bruton’s Tyrosine Kinase Hematological Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Bruton’s Tyrosine Kinase Hematological Cancer?
• How many therapies are in-development by each company for Bruton’s Tyrosine Kinase Hematological Cancer treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Bruton’s Tyrosine Kinase Hematological Cancer treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bruton’s Tyrosine Kinase Hematological Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bruton’s Tyrosine Kinase Hematological Cancer and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Bruton’s Tyrosine Kinase Hematological Cancer?
• What are the global historical and forecasted markets of Bruton’s Tyrosine Kinase Hematological Cancer?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Bruton’s Tyrosine Kinase Hematological Cancer market
• Organize sales and marketing efforts by identifying the best opportunities for Bruton’s Tyrosine Kinase Hematological Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Bruton’s Tyrosine Kinase Hematological Cancer market
• To understand the future market competition in the Bruton’s Tyrosine Kinase Hematological Cancer market